Director at SeaStar Medical (ICU) awarded 3,000 RSUs in grant

Rhea-AI Filing Summary

SeaStar Medical Holding Corp director John Neuman reported a stock-based award. On February 6, 2026, he received 3,000 shares of common stock at a stated price of $0, reported as an acquired transaction.

After this grant, Neuman beneficially owns 12,200 shares of SeaStar Medical common stock in direct form. The filing notes that the 3,000-share award represents restricted stock units (RSUs) that will vest in full on February 6, 2027.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Neuman John

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, par value $0.0001	3,000	$0.00	--

Holdings After Transaction: Common Stock, par value $0.0001 — 12,200 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neuman John

(Last) (First) (Middle)

3513 BRIGHTON BLVD

SUITE 410

(Street)

DENVER C0 80216

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SeaStar Medical Holding Corp [ ICU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001	02/06/2026		A		3,000(1)	A	$0	12,200	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a RSU award. The RSUs will vest in full on February 6, 2027.

Remarks:

Ex. 24.1 - Power of Attorney

	/s/ Eric Schlorff as-attorney-in-fact	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SeaStar Medical (ICU) report for John Neuman?

SeaStar Medical reported that director John Neuman received 3,000 shares of common stock on February 6, 2026. The transaction was coded as an acquisition at a stated price of $0, increasing his direct beneficial ownership to 12,200 shares.

How many SeaStar Medical (ICU) shares does director John Neuman now own?

After the reported award, director John Neuman beneficially owns 12,200 shares of SeaStar Medical common stock. This total reflects the impact of the February 6, 2026 grant of 3,000 shares reported as acquired in the Form 4 filing.

Was the SeaStar Medical (ICU) insider award a restricted stock unit grant?

Yes. The 3,000-share award to director John Neuman is described as a restricted stock unit (RSU) grant. According to the filing, these RSUs will vest in full on February 6, 2027, subject to the terms of the award.

What is the vesting schedule for John Neuman’s RSUs at SeaStar Medical (ICU)?

The filing states that John Neuman’s 3,000 restricted stock units will vest in full on February 6, 2027. This means the RSUs convert into shares on that date, assuming the award’s conditions are satisfied under the company’s equity plan.

How was the price reported for John Neuman’s SeaStar Medical (ICU) stock grant?

The 3,000-share grant to John Neuman was reported with a transaction price of $0 per share. This reflects that the award is stock-based compensation, recorded as an acquisition rather than an open-market purchase for cash consideration.